Reprogramming the immune system for cancer: The promise of CAR T-cell therapy and beyond

Medicine and Dentistry

• Malignant Neoplasm 100%
• Immune System 100%
• Chimeric Antigen Receptor T-Cell Immunotherapy 100%
• Solid Malignant Neoplasm 60%
• Cancer 40%
• Tumor Microenvironment 40%
• Targeted Therapy 40%
• Cancer Growth 40%
• Immunotherapy 40%
• Immunosuppressive Drug 40%
• Neoplasm 20%
• Cytokine 20%
• Mortality Rate 20%
• Cancer Cell 20%
• Infusion 20%
• Cancer Therapy 20%
• Leukemia 20%
• Lung Cancer 20%
• Cancer Treatment 20%
• Immunocompetent Cell 20%
• Tumor Vaccine 20%
• T Cell 20%
• Cancer Mortality 20%
• Therapeutic Use 20%
• Chimeric Antigen Receptor T-Cell 20%
• Melanoma 20%
• T Lymphocyte Receptor 20%
• Chimeric Antigen Receptor 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Chimeric Antigen Receptor 100%
• Solid Malignant Neoplasm 42%
• Tumor Microenvironment 28%
• Cancer Growth 28%
• Immunotherapy 28%
• Immunosuppressive Agent 28%
• Lung Cancer 14%
• Neoplasm 14%
• Mortality Rate 14%
• Cytokine 14%
• Leukemia 14%
• Molecular Target 14%
• Therapeutic Use 14%
• Melanoma 14%
• Cancer Mortality 14%
• Tumor Vaccine 14%